Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02538627 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02538627: Clinical Trial Phase 1 study, sponsored by Merrimack Pharmaceuticals.
NCT02538627 is a Phase 1 study that was terminated before completion, run by Merrimack Pharmaceuticals. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02538627, a Phase 1 study, was terminated before completion, sponsored by Merrimack Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
Interventions
- DRUG trametinib
- DRUG MM-121
- DRUG MM-141
- DRUG MM-151
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-10-05 |
| Phase | Phase 1 |
Why NCT02538627 stopped before completion
NCT02538627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which trametinib is the first listed.
NCT02538627 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02538627 about?
NCT02538627 is a clinical study titled "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib". This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
What is the current status of trial NCT02538627?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2015-08. Estimated completion is 2016-10-05.
What interventions are being tested in trial NCT02538627?
The interventions under investigation include: trametinib (DRUG), MM-121 (DRUG), MM-141 (DRUG), MM-151 (DRUG).
Who is sponsoring clinical trial NCT02538627?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02538627's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia